Thus, PPAR gamma agonists have been reported as new and potentially efficacious treatment of inflammation, diabetes, obesity, cancer, AD, and schizophrenia [112]. This evidence concerns the gene PPARG and obesity due to melanocortin 4 receptor deficiency.